When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase stock, like in Zentalis Pharmaceuticals, Inc.'s (NASDAQ:ZNTL) instance, it's good news for shareholders.
Although we don't think shareholders should simply follow insider transactions, we would consider it foolish to ignore insider transactions altogether.
Zentalis Pharmaceuticals Insider Transactions Over The Last Year
Over the last year, we can see that the biggest insider purchase was by Independent Chairman of the Board David Johnson for US$168k worth of shares, at about US$9.88 per share. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of US$12.31. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.
Over the last year, we can see that insiders have bought 22.00k shares worth US$219k. On the other hand they divested 4.90k shares, for US$56k. In the last twelve months there was more buying than selling by Zentalis Pharmaceuticals insiders. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
NasdaqGM:ZNTL Insider Trading Volume May 8th 2024
Zentalis Pharmaceuticals is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.
Insider Ownership
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. A high insider ownership often makes company leadership more mindful of shareholder interests. It appears that Zentalis Pharmaceuticals insiders own 2.3% of the company, worth about US$20m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.
What Might The Insider Transactions At Zentalis Pharmaceuticals Tell Us?
It doesn't really mean much that no insider has traded Zentalis Pharmaceuticals shares in the last quarter. But insiders have shown more of an appetite for the stock, over the last year. Insiders own shares in Zentalis Pharmaceuticals and we see no evidence to suggest they are worried about the future. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Zentalis Pharmaceuticals. In terms of investment risks, we've identified 2 warning signs with Zentalis Pharmaceuticals and understanding these should be part of your investment process.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
當單個內部人士購買股票時,這通常不是什麼大交易。 然而,當多個內部人士購買股票時,就像 Zentalis Pharmaceuticals, Inc.(納斯達克股票代碼:ZNTL)的例子一樣,這對股東來說是個好消息。
儘管我們認爲股東不應該只關注內幕交易,但我們認爲完全忽視內幕交易是愚蠢的。
Zentalis Pharmicals去年的內幕交易
在過去的一年中,我們可以看到,最大的內幕收購是獨立董事會主席戴維·約翰遜以每股約9.88美元的價格購買了價值16.8萬美元的股票。儘管我們希望看到內幕買盤,但我們注意到,此次大宗收購的價格遠低於最近的12.31美元。儘管這確實表明內部人士認爲該股在較低的價格下被低估,但這筆交易並沒有告訴我們他們對當前價格的看法。
在過去的一年中,我們可以看到內部人士購買了價值21.9萬美元的22.00萬股股票。另一方面,他們以5.6萬美元的價格剝離了4.9萬股股票。在過去的十二個月中,Zentalis製藥內部人士的買入量多於賣出量。你可以在下面看到過去 12 個月的內幕交易(公司和個人)的直觀描述。如果你想確切地知道誰賣了、賣了多少以及何時出售,只需點擊下圖!
納斯達克通用汽車公司:ZNTL 內幕交易量 2024 年 5 月 8 日
Zentalis製藥並不是內部人士唯一買入的股票。因此,看看這份免費的內幕收購成長型公司名單。
內部所有權
測試公司領導者與其他股東之間一致性的另一種方法是查看他們擁有多少股份。較高的內部所有權通常會使公司領導層更加關注股東的利益。看來Zentalis製藥內部人士擁有該公司2.3%的股份,價值約2000萬美元。當然,我們在其他地方看到了更高的內部所有權水平,但這些持股足以表明內部人士與其他股東之間的一致性。
Zentalis Pharmicals的內幕交易可能告訴我們什麼?
上個季度沒有內部人士交易過Zentalis製藥的股票,這並沒有多大意義。但是,在過去的一年中,內部人士對該股表現出了更大的興趣。內部人士擁有Zentalis Pharmicals的股份,我們沒有發現任何證據表明他們對未來感到擔憂。除了了解正在進行的內幕交易外,確定Zentalis Pharmicals面臨的風險也是有益的。在投資風險方面,我們已經向Zentalis Pharmicals確定了兩個警告信號,我們知道這些信號應該是您投資過程的一部分。
當然,通過尋找其他地方,你可能會找到一筆不錯的投資。因此,來看看這份有趣的公司的免費清單吧。
就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接聯繫我們。或者,也可以發送電子郵件至編輯團隊 (at) simplywallst.com。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。